Genetic alterations of FMS-Like Tyrosine Kinase 3 (FLT3) characterize about 25–30% of AML cases [51] as well as several solid tumors such as lung adenocarcinoma and gastrointestinal cancer [52]. The gene discussed is FLT3; the disease is acute myeloid leukemia.